Is a Generic Dalteparin Available in the US?
No generic dalteparin is FDA-approved for prescription in the US. Dalteparin (brand name Fragmin) is a low molecular weight heparin (LMWH) supplied by Pfizer. Unlike unfractionated heparin, LMWHs like dalteparin have complex manufacturing processes that make generic approval challenging. The FDA has not approved any generic dalteparin, as it requires proving sameness in molecular weight distribution, anticoagulant activity, and clinical performance.[1][2]
Why No Generic Yet?
Dalteparin lacks an approved Abbreviated New Drug Application (ANDA) pathway due to its biologic-like complexity. The FDA classifies LMWHs as drugs, not biologics, but requires extensive sameness testing. No company has met these standards for dalteparin specifically, unlike enoxaparin (Lovenox), which has generics.[1][3]
Can Doctors Prescribe Something Else Instead?
Physicians often switch to alternatives rather than generics:
- Enoxaparin (Lovenox generics): FDA-approved generics available since 2010. Interchangeable for most DVT prophylaxis/treatment uses, though dosing differs slightly (1 mg/kg vs. dalteparin's 200 units/kg).[2][4]
- Other LMWHs: Tinzaparin (Innohep) has no generic; fondaparinux (Arixtra) is a synthetic pentasaccharide alternative.
- Unfractionated heparin: Cheaper generic option, but requires lab monitoring (aPTT) unlike fixed-dose LMWHs.
Switches depend on indication (e.g., cancer-associated thrombosis favors dalteparin per guidelines).[5]
When Might a Generic Dalteparin Launch?
Key patents on Fragmin formulations expired around 2015-2020, but no generics filed or approved.[6] Check DrugPatentWatch.com for updates: Fragmin patents. Potential delays from litigation or FDA hurdles; biosimilar-like approval could take years.
Cost and Insurance Impact
Fragmin costs $300-600 per prefilled syringe (30 mg dose). Generic enoxaparin runs $20-50 per dose, often covered interchangeably by insurance for non-cancer uses. Medicare Part D may require prior authorization for brand switches.[4][7]
Patient Risks with Substitution
Alternatives carry similar bleeding risks (1-3% major bleeds), but differences exist:
- Dalteparin preferred in cancer patients (CLOT trial data).[5]
- HIT (heparin-induced thrombocytopenia) risk comparable across LMWHs.
Consult guidelines (ACCP/ASH) before switching; renal impairment may favor dose-adjusted options.[2][5]
Sources
[1]: FDA Orange Book - Fragmin
[2]: FDA LMWH Guidance
[3]: Drugs.com - Dalteparin Generics
[4]: GoodRx - Enoxaparin Pricing
[5]: NEJM CLOT Trial
[6]: DrugPatentWatch - Fragmin
[7]: CMS Medicare Coverage